Principal Accounting Officer and Former Interim Principal Financial Officer, Vice President · ROCKET PHARMACEUTICALS, INC. (RCKT)

John Militello

A named executive officer of ROCKET PHARMACEUTICALS in every fiscal year CompBrief holds from FY2020 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,175,588

Salary $341,455Stock awards $249,743

FY2023: $1,527,570

6th of 6 named executive officers at Rocket Pharmaceuticals by FY2024 total.

6 named officers on file for ROCKET PHARMACEUTICALS, FY2024

John Militello’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 11 equity grants, each cited to its filing
  • RCKT’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ROCKET PHARMACEUTICALS’s whole pay program stands against its peers

  • ROCKET PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RCKT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get John Militello’s full pay file as a PDF — free

More than this page: up to 10 years of John’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

John Militello compensation by year

ROCKET PHARMACEUTICALS Summary Compensation Table · all 4 fiscal years held
In US dollars, as ROCKET PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2022FY2023FY2024
Salary$257,233$376,788$409,014$341,455
Bonus$117,150$0$5,000$0
Stock awards$0$664,976$332,985$249,743
Option awards$617,270$584,988$666,991$500,234
Non-equity incentive$0$104,133$100,014$69,205
Pension and deferred compensation$0$0$0$0
All other$11,400$20,500$13,566$14,951
Total$1,003,053$1,751,386$1,527,570$1,175,588

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ROCKET PHARMACEUTICALS, INC. DEF 14A filed April 30, 2025, accession 0001140361-25-016656, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ROCKET PHARMACEUTICALS, INC. filed document, accession 0001140361-25-016656. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2025.

$1.0M
$1.8M
$1.5M
$1.2M
FY20
FY22
FY23
FY24
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU33,450$420,467—
Option4,814—$13.12
Option21,131—$20.04
Option2,262—$19.05
Option24,545—$30.01

Per the Outstanding Equity Awards at Fiscal Year-End table in ROCKET PHARMACEUTICALS, INC.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

34 Form 4 lines since the FY2024 proxy (filed April 30, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-05-26Disposition to the issuer derivative—10,000—0
2026-05-26Disposition to the issuer derivative—2,000—0
2026-05-26Grant or award derivative—51,509—51,509
2026-05-26Disposition to the issuer derivative—18,000—0
2026-05-26Grant or award derivative—9,091—9,091
2026-05-26Disposition to the issuer derivative—49,798—0
2026-05-26Grant or award derivative—24,899—24,899
2026-05-26Disposition to the issuer derivative—10,000—0

The 8 most recent of 34 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

ROCKET PHARMACEUTICALS’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Gaurav ShahChief Executive Officer$6,841,407
Kinnari PatelPresident, Head of R&D and Chief Operating Officer$6,696,055
Aaron OndreyChief Financial Officer, Principal Financial Officer$2,989,763
Jonathan SchwartzChief Medical and Gene Therapy Officer$2,364,309
Martin WilsonGeneral Counsel and Chief Corporate Officer, Senior VP$2,113,954
John Militello · this pagePrincipal Accounting Officer and Former Interim Principal Financial Officer, Vice President$1,175,588

The full ROCKET PHARMACEUTICALS compensation record

free company brief

This page is one person within ROCKET PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ROCKET PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ROCKET PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

John Militello's compensation dossier · One-time report. No refunds.